Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DR26FFLN5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The award, issued on November 3, 2025, with completion targeted for November 4, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group is fulfilling this delivery order under its single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, represents a $499.999 billion ceiling value vehicle with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. As one of multiple regional prime vendor contractors under the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group serves as a critical supplier of branded and generic pharmaceuticals, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. The company's established performance across numerous delivery orders demonstrates its capability to fulfill specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFLN5?
SPE2DR26FFLN5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DR26FFLN5 worth?
The government has obligated $4,255 on SPE2DR26FFLN5.
Is contract SPE2DR26FFLN5 an order under another contract?
Yes. SPE2DR26FFLN5 is a delivery order under SPE2DR25D9227, an indefinite delivery contract.
Was contract SPE2DR26FFLN5 competed?
The extent of competition for SPE2DR26FFLN5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award